Highlights
- The LIDA trial (NCT05010590) established that 3 months of romosozumab followed by 9 months of denosumab is non-inferior to 12 months of romosozumab for total hip BMD.
- Romosozumab’s unique dual-action mechanism (stimulating formation while inhibiting resorption) is most potent in the initial months, providing a biological rationale for shorter treatment windows.
- Abbreviated therapy could significantly lower healthcare costs, reduce the burden of monthly injections, and potentially mitigate concerns regarding cardiovascular risk associated with longer exposure.
- Sequential therapy remains crucial: transitioning to an antiresorptive agent like denosumab is necessary to maintain the bone density gains achieved during the anabolic phase.
Background
Postmenopausal osteoporosis remains a major public health challenge, characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to an increased risk of fragility fractures. These fractures are associated with significant morbidity, loss of independence, and increased mortality. For decades, the therapeutic landscape was dominated by antiresorptive agents, primarily bisphosphonates. However, the emergence of anabolic agents has shifted the paradigm toward an “anabolic-first” strategy for patients at very high risk of fracture.
Romosozumab, a humanized monoclonal antibody that binds to and inhibits sclerostin, represents the most significant recent advancement in this field. Sclerostin, produced by osteocytes, is a potent inhibitor of bone formation via the Wnt/β-catenin signaling pathway. By blocking sclerostin, romosozumab exerts a dual effect: it rapidly increases bone formation and, to a lesser extent, decreases bone resorption. This “uncoupling” of bone remodeling leads to rapid and substantial increases in bone mineral density (BMD).
Despite its efficacy, the standard 12-month course of romosozumab presents challenges. First, the anabolic effect—as measured by bone formation markers like procollagen type 1 N-terminal propeptide (P1NP)—is transient, peaking within the first 1–3 months and returning toward baseline by 12 months. Second, the drug is costly and requires monthly healthcare provider-administered injections. Third, early clinical trials (ARCH) identified a potential, though debated, increase in serious cardiovascular adverse events compared to alendronate. Consequently, exploring whether a shorter, more targeted course of romosozumab can achieve comparable outcomes is of paramount clinical and economic importance.
Key Content
Mechanistic Insights and the Sclerostin Pathway
The efficacy of romosozumab is rooted in the biology of the osteocyte. Sclerostin acts as a brake on the Wnt pathway by binding to LRP5/6 receptors on osteoblasts. When romosozumab removes this brake, osteoblast activity is markedly up-regulated. Interestingly, sclerostin also influences the expression of RANKL (Receptor Activator of Nuclear Factor kappa-B Ligand), meaning its inhibition indirectly suppresses osteoclast-mediated resorption. The LIDA trial leverages the observation that the maximum divergence between formation and resorption occurs very early in treatment. By the six-month mark, the “anabolic window” begins to close as bone formation markers decline, likely due to compensatory mechanisms within the bone microenvironment.
The LIDA Trial: Study Design and Participant Profile
The LIDA trial was a 12-month, prospective, open-label, randomized, controlled, non-inferiority trial conducted at a single academic medical center in the USA. It specifically targeted postmenopausal women at high risk of fracture. The study randomized 50 participants into two distinct tracks:
- The 3-month ROMO Group: Participants received romosozumab (210 mg monthly) for 3 months, followed immediately by denosumab (60 mg every 6 months) for the remaining 9 months.
- The 12-month ROMO Group: Participants received the standard 12-month course of romosozumab (210 mg monthly).
The primary endpoint was the percentage change in total hip BMD at 12 months. The hip was selected as the primary site because of its clinical relevance to fracture-related mortality and because it typically responds more slowly to therapy than the lumbar spine, making it a robust site for testing non-inferiority. The non-inferiority margin was set at 2%, a clinically significant threshold in osteoporosis research.
Analysis of Primary and Secondary Outcomes
The findings of the LIDA trial provide strong evidence for the efficacy of the abbreviated regimen. In the modified intention-to-treat analysis, the results were as follows:
- Total Hip BMD Change: The 3-month ROMO group showed a 5.7% (SD 3.3) increase, while the 12-month ROMO group showed a 6.0% (SD 3.2) increase. The difference between the groups was well within the prespecified 2% non-inferiority margin.
- Lumbar Spine BMD: Although not the primary endpoint, the increases in the lumbar spine were substantial in both groups, consistent with previous romosozumab trials (FRAME and ARCH).
- Bone Turnover Markers: As expected, the 3-month group saw a transition from an anabolic profile to an antiresorptive profile (due to denosumab) after month 3, while the 12-month group maintained the romosozumab-specific profile for the full duration.
Safety and Tolerability
Safety data showed no significant discrepancies between the two groups. Reported adverse events included musculoskeletal pain (back pain, joint pain), fatigue, and injection site reactions. Crucially, there were no imbalances in cardiovascular events in this small cohort, though the trial was not powered to detect rare safety signals. The lower cumulative dose of romosozumab in the 3-month group (630 mg vs. 2520 mg) theoretically reduces the duration of exposure to any potential cardiovascular risks associated with sclerostin inhibition.
Contextualizing LIDA with Previous Evidence
To understand the LIDA trial’s impact, it must be compared to pivotal trials:
- FRAME Trial (2016): Demonstrated that 12 months of romosozumab followed by denosumab reduced vertebral fractures by 73% compared to placebo followed by denosumab.
- ARCH Trial (2017): Showed that 12 months of romosozumab followed by alendronate was superior to alendronate alone in reducing fracture risk in high-risk women.
- STRUCTURE Trial (2018): Showed that romosozumab increased BMD more significantly than teriparatide in women transitioning from bisphosphonate therapy.
The LIDA trial adds a new dimension by suggesting that the “heavy lifting” of romosozumab occurs in the first quarter of the standard treatment year. By switching to denosumab early, clinicians can “lock in” the gains made during the peak anabolic phase.
Expert Commentary
The LIDA trial represents a critical step toward precision medicine in metabolic bone disease. From a mechanistic standpoint, the findings validate the hypothesis that the waning bone formation markers observed in earlier studies reflect a diminishing marginal utility of romosozumab after the initial 3–4 months. For clinicians, this opens the door to a more flexible dosing strategy.
One of the most compelling arguments for the 3-month regimen is economic. In many healthcare systems, romosozumab is restricted due to its high cost. Reducing the treatment duration by 75% while maintaining non-inferior BMD gains could lead to a massive improvement in the cost-effectiveness ratio, potentially allowing more patients to access this potent therapy. Furthermore, the convenience factor cannot be overstated; reducing the number of clinic visits for injections from 12 to 3 (plus the biannual denosumab) significantly improves patient adherence and quality of life.
However, some caution is warranted. The LIDA trial was a small study (n=50) conducted at a single center. While BMD is a validated surrogate marker for fracture risk, the trial was not powered to assess fracture outcomes directly. It remains to be seen if the microarchitectural improvements achieved in 3 months are as resilient as those achieved in 12 months when subjected to long-term mechanical stress. Additionally, the timing of the transition to denosumab is critical. Because romosozumab’s effects are reversible, the subsequent antiresorptive therapy must be initiated promptly to prevent rapid bone loss.
The cardiovascular safety profile of romosozumab remains a point of discussion. While the absolute risk is low, a shorter exposure period is inherently attractive for patients with pre-existing cardiovascular risk factors who might otherwise be excluded from romosozumab therapy according to current guidelines.
Conclusion
The LIDA trial successfully demonstrated that a 3-month course of romosozumab followed by 9 months of denosumab is non-inferior to a standard 12-month romosozumab course for increasing total hip BMD in high-risk postmenopausal women. This study challenges the “one size fits all” 12-month dosing paradigm and provides a biological and clinical framework for abbreviated anabolic therapy.
Future research should focus on larger, multi-center trials to confirm these findings and evaluate fracture incidence. Additionally, investigating whether this abbreviated approach is equally effective in patients transitioning from other therapies (like long-term bisphosphonates) will be essential. For now, the LIDA trial offers a promising pathway toward more accessible, cost-effective, and patient-centered management of severe osteoporosis.
References
- Leder BZ, Ramchand SK, Jordan M, et al. 3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial. Lancet Diabetes Endocrinol. 2026;14(3):216-222. PMID: 41621431.
- Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016;375(16):1532-1543. PMID: 27641548.
- Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017;377(15):1417-1427. PMID: 28905785.
- Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, et al. Effects of Romosozumab Compared With Teriparatide on Bone Density and Fracture Risk: A Meta-analysis. JAMA Netw Open. 2018;1(6):e183161.
